Attention-Deficit Hyperactivity Disorder (ADHD) Treatment Access Expands in New Zealand
New Zealand is making significant strides in improving access to ADHD treatment for its citizens. As of February 1, 2026, the country's prescribing rules for stimulant medications have undergone a transformative change, allowing for more flexible and accessible assessment and diagnosis processes. This update aims to address the challenges faced by individuals with ADHD by ensuring timely and comprehensive care.
Previously, obtaining an ADHD diagnosis and prescription required a complex process. General practitioners (GPs) and nurse practitioners could only prescribe ADHD medications if they received a written recommendation from a paediatrician or psychiatrist, or if the patient had already been diagnosed and received a prescription. This limitation often led to delays in treatment, especially for adults who might not have had access to these specialists.
The new regulations empower vocationally registered specialist GPs and nurse practitioners to initiate stimulant treatments for adults aged 18 and above who have been diagnosed with ADHD. This expansion of prescribing authority is a significant step towards building a robust specialist workforce and establishing pathways for safe and thorough assessments.
Dr. Jin Russell, Chief Clinical Advisor for Child and Youth, emphasizes that the changes do not require patients to take any additional steps to access ADHD assessments. GPs remain the primary point of contact, guiding patients to the appropriate services in their area. While these services will not be immediately available everywhere, the goal is to increase the number of pathways for individuals seeking ADHD treatment.
It's important to note that ADHD assessments are intricate and time-consuming, typically requiring one to two hours and possibly spanning multiple appointments. The cost of these assessments can vary depending on the type of service, local funding arrangements, and the duration of the assessment and follow-up care.
The new rules allow GPs and nurse practitioners to prescribe publicly funded stimulant medications for ADHD, including methylphenidate, dexamfetamine, and lisdexamfetamine. Dr. Russell highlights the ongoing global shortages of ADHD stimulant medications due to high demand and limited manufacturing capacity. Pharmac, the New Zealand Medicines and Medical Devices Safety Authority, is actively managing supply and exploring alternative brands and treatments to meet the growing demand.
This expansion of ADHD treatment access is a significant step towards ensuring that New Zealanders with ADHD receive the care they need. By simplifying the assessment and prescribing process, the country is taking a proactive approach to addressing the challenges associated with ADHD management.
